Unless the government intervenes to lower the price or forces insurers to cover the drugs, they will remain out of range for ...

Nearly 75% of Americans are classified as overweight or obese. Addressing our nation's health crisis requires much more than ...

Not at all. Novo Nordisk's investigational weight loss therapy, CagriSema, combines semaglutide (the active ingredient in ...

Although Novo will still make a mind-blowing amount of money from its existing obesity drugs in the coming years (its ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their ...

Plenty of people want to lose weight in 2025, but here's why many may actually get there thanks to GLP-1 drugs.

Alzheimer's, addiction, cardiovascular diseases, kidney disorders, sleep apnoea, diabetes, obesity, and overweight.

GLP-1 receptor agonists (GLP-1RAs) on multiple fronts. They continued to expand into new indications, and provide their developers with both rich remuneration and scientific acclamation. There are now ...

Starting in the new year, Independence Blue Cross, the region’s largest health insurer, will no longer cover anti-obesity drugs like Ozempic and Wegovy when they’re prescribed solely for weight loss.

Tirzepatide may be more effective than semaglutide in helping people lose weight. At least that's the findings from recent ...

Director-General of the World Health Organization, Tedros Adhanom Ghebreyesus, says he was close to the departure lounge when it was hit. Ukraine's air force says it detected 184 missiles and ...